{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:14:16Z","timestamp":1790162056879,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019346","name":"Instituto Nacional de Cancerolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019346","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute of Cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pleural mesothelioma (PM) remains a lethal but preventable disease whose burden is shifting toward low- and middle-income countries (LMICs) where asbestos use has persisted or has only recently been banned. This study describes the clinical characteristics, management patterns, and prognostic factors of PM in a contemporary Colombian cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of adults with histologically confirmed pleural mesothelioma diagnosed at a tertiary referral cancer center in Bogot\u00e1, Colombia, from January 1, 2011, to December 31, 2023. Overall survival (OS) was defined from the histologic diagnosis date to death from any cause; patients without a recorded death were censored at the last documented oncologic contact. Real-world progression-free survival (PFS) was defined from diagnosis to documented progression (radiologic or clinician-documented) or death, whichever occurred first; patients without progression or death were censored at last contact. Survival was estimated using Kaplan\u2013Meier methods and modeled using Cox proportional hazards regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 106 patients (mean age, 63.2\u00a0years; 73.6% male; 84.9% epithelioid histology). There were 105 deaths (1 OS censor). Median OS was 9.9\u00a0months (95% CI, 7.1\u201314.1), with 12- and 24\u00a0month OS of 46.2% and 12.3%. Real-world PFS included 105 events (1 PFS censor). Median PFS was 8.1\u00a0months (95% CI, 6.2\u20139.4), with 12- and 24\u00a0month PFS of 30.2% and 6.6%. In multivariable analyses focused on baseline prognostic factors, ECOG performance status 2\u20133 was associated with shorter OS and PFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this contemporary Colombian cohort, OS and PFS were short, and baseline functional status was strongly associated with outcomes. Treatment-stratified survival patterns are reported descriptively and should not be interpreted as comparative effectiveness. These data add regional evidence for pleural mesothelioma prognosis in routine practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-026-04337-1","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:43:35Z","timestamp":1777574615000},"page":"4839-4848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and prognostic factors in pleural mesothelioma: insights from a Latin American cohort"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3649-9515","authenticated-orcid":false,"given":"Ricardo","family":"Brug\u00e9s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Carvajal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Navarrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Parra-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"4337_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69:402\u201329. https:\/\/doi.org\/10.3322\/caac.21572.","journal-title":"CA Cancer J Clin"},{"key":"4337_CR2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00953-2019","volume":"55","author":"A Scherpereel","year":"2020","unstructured":"Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55:1900953. https:\/\/doi.org\/10.1183\/13993003.00953-2019.","journal-title":"Eur Respir J"},{"issue":"10272","key":"4337_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375\u201386. https:\/\/doi.org\/10.1016\/S0140-6736(20)32714-8.","journal-title":"Lancet."},{"key":"4337_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33:129\u201342. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005.","journal-title":"Ann Oncol"},{"key":"4337_CR5","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.2341","volume":"85","author":"E Algranti","year":"2019","unstructured":"Algranti E, Ramos-Bonilla JP, Terracini B, Santana VS, Comba P, Pasetto R, et al. Prevention of asbestos exposure in Latin America within a global public health perspective. Ann Glob Health. 2019;85:49. https:\/\/doi.org\/10.5334\/aogh.2341.","journal-title":"Ann Glob Health"},{"key":"4337_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33:488\u201399. https:\/\/doi.org\/10.1016\/j.annonc.2022.01.074.","journal-title":"Ann Oncol"},{"key":"4337_CR7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/1759-7714.12967","volume":"10","author":"L Rojas","year":"2019","unstructured":"Rojas L, Cardona AF, Trejo-Rosales R, Zatarain-Barr\u00f3n ZL, Ram\u00edrez-Tirado L-A, Ruiz-Pati\u00f1o A, et al. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP). Thorac Cancer. 2019;10:508\u201318. https:\/\/doi.org\/10.1111\/1759-7714.12967.","journal-title":"Thorac Cancer"},{"key":"4337_CR8","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.5858\/arpa.2023-0304-RA","volume":"148","author":"AN Husain","year":"2024","unstructured":"Husain AN, Chapel DB, Attanoos R, Beasley MB, Brcic L, Butnor K, et al. Guidelines for pathologic diagnosis of mesothelioma: 2023 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2024;148:1251\u201371. https:\/\/doi.org\/10.5858\/arpa.2023-0304-RA.","journal-title":"Arch Pathol Lab Med"},{"key":"4337_CR9","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","volume":"73","author":"I Woolhouse","year":"2018","unstructured":"Woolhouse I, Bishop L, Darlison L, De Fonseka D, Edey A, Edwards J, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax. 2018;73:i1-30. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-211321.","journal-title":"Thorax"},{"key":"4337_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1200\/JCO.1998.16.1.145","volume":"16","author":"D Curran","year":"1998","unstructured":"Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145\u201352. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.145.","journal-title":"J Clin Oncol"},{"key":"4337_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","volume":"11","author":"A Bill\u00e9","year":"2016","unstructured":"Bill\u00e9 A, Krug LM, Woo KM, Rusch VW, Zauderer MG. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma. J Thorac Oncol. 2016;11:249\u201355. https:\/\/doi.org\/10.1016\/j.jtho.2015.10.003.","journal-title":"J Thorac Oncol"},{"key":"4337_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2025.103202","volume":"56","author":"O Arrieta","year":"2025","unstructured":"Arrieta O, Palomares-Palomares CB, G\u00f3mez-Garc\u00eda AP, Rios-Garcia E, Hernandez-Martinez J-M, Turcott JG, et al. Narrowing the gap: understanding lung cancer care intervals and their barriers in Latin American low and middle-income countries. Arch Med Res. 2025;56:103202. https:\/\/doi.org\/10.1016\/j.arcmed.2025.103202.","journal-title":"Arch Med Res"},{"key":"4337_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00393","volume":"9","author":"\u00d3 Gamboa","year":"2023","unstructured":"Gamboa \u00d3, Buitrago G, Pati\u00f1o AF, Agudelo NR, Espinel LS, Eslava-Schmalbach J, et al. Fragmentation of care and its association with survival and costs for patients with breast cancer in Colombia. JCO Glob Oncol. 2023;9:e2200393. https:\/\/doi.org\/10.1200\/GO.22.00393.","journal-title":"JCO Glob Oncol"},{"key":"4337_CR14","doi-asserted-by":"publisher","DOI":"10.5334\/aogh.4166","volume":"89","author":"JP Ramos-Bonilla","year":"2023","unstructured":"Ramos-Bonilla JP, Giraldo M, Marsili D, Pasetto R, Terracini B, Mazzeo A, et al. An approach to overcome the limitations of surveillance of asbestos related diseases in low- and middle-income countries: what we learned from the Sibat\u00e9 Study in Colombia. Ann Glob Health. 2023;89:64. https:\/\/doi.org\/10.5334\/aogh.4166.","journal-title":"Ann Glob Health"},{"key":"4337_CR15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","volume":"28","author":"M Cigognetti","year":"2015","unstructured":"Cigognetti M, Lonardi S, Fisogni S, Balzarini P, Pellegrini V, Tironi A, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043\u201357. https:\/\/doi.org\/10.1038\/modpathol.2015.65.","journal-title":"Mod Pathol"},{"key":"4337_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003956","volume":"10","author":"R Govindan","year":"2022","unstructured":"Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. J Immunother Cancer. 2022;10:e003956. https:\/\/doi.org\/10.1136\/jitc-2021-003956.","journal-title":"J Immunother Cancer"},{"key":"4337_CR17","doi-asserted-by":"publisher","unstructured":"Armato SG, Nowak AK, Francis RJ, Katz SI, Kholmatov M, Blyth KG, et al. Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group. Lung Cancer. Amsterdam, Netherlands; 2022;164:76\u201383. https:\/\/doi.org\/10.1016\/j.lungcan.2021.12.008","DOI":"10.1016\/j.lungcan.2021.12.008"},{"key":"4337_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S2213-2600(24)00119-X","volume":"12","author":"E Lim","year":"2024","unstructured":"Lim E, Waller D, Lau K, Steele J, Pope A, Ali C, et al. Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial. Lancet Respir Med. 2024;12:457\u201366. https:\/\/doi.org\/10.1016\/S2213-2600(24)00119-X.","journal-title":"Lancet Respir Med"},{"key":"4337_CR19","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(11)70149-8.","journal-title":"Lancet Oncol"},{"issue":"10419","key":"4337_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","volume":"402","author":"Q Chu","year":"2023","unstructured":"Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402(10419):2295\u2013306. https:\/\/doi.org\/10.1016\/S0140-6736(23)01613-6.","journal-title":"Lancet."},{"key":"4337_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","volume":"9","author":"L Calabr\u00f2","year":"2021","unstructured":"Calabr\u00f2 L, Rossi G, Morra A, Rosati C, Cutaia O, Daffin\u00e0 MG, et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir Med. 2021;9:969\u201376. https:\/\/doi.org\/10.1016\/S2213-2600(21)00043-6.","journal-title":"Lancet Respir Med"},{"key":"4337_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.cllc.2024.09.005","volume":"25","author":"D Enrico","year":"2024","unstructured":"Enrico D, Gomez JE, Aguirre D, Tissera NS, Tsou F, Pupareli C, et al. Efficacy of first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma: a multicenter real-world study (ImmunoMeso LATAM). Clin Lung Cancer. 2024;25:723-731.e2. https:\/\/doi.org\/10.1016\/j.cllc.2024.09.005.","journal-title":"Clin Lung Cancer"},{"key":"4337_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.annonc.2024.12.014","volume":"36","author":"E Felip","year":"2025","unstructured":"Felip E, Popat S, Dafni U, Ribi K, Pope A, Cedres S, et al. A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial. Ann Oncol. 2025;36:548\u201360. https:\/\/doi.org\/10.1016\/j.annonc.2024.12.014.","journal-title":"Ann Oncol"},{"key":"4337_CR24","doi-asserted-by":"publisher","unstructured":"Forde PM, Nowak AK, Hughes BGM, Kok PS, Brown C, Sun Z, et al. Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R). J Clin Oncol. Wolters Kluwer; 2023;41:TPS8599\u2013TPS8599. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS8599","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8599"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04337-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04337-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:41:22Z","timestamp":1790160082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04337-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":24,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4337"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04337-1","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no relevant financial or non-financial conflicts of interest related to the content of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}